Welcome to our dedicated page for Alpha Tau Medical SEC filings (Ticker: DRTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alpha Tau Medical Ltd. (NASDAQ: DRTS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Alpha Tau files reports such as Form 20-F annual reports and Form 6-K current reports under the Securities Exchange Act of 1934, reflecting its status as a clinical-stage oncology therapeutics company developing the Alpha DaRT alpha-radiation therapy for solid tumors.
Through these filings, investors can review information that Alpha Tau has furnished about its operations, clinical development, and financial position. Recent Form 6-K reports have attached press releases covering topics such as third quarter financial results and corporate updates, receipt of a radioactive material license for the New Hampshire manufacturing facility, and participation in major healthcare conferences. These documents also indicate how certain reports and exhibits are incorporated by reference into Alpha Tau’s registration statements on Form F-3 and Form S-8.
For those analyzing DRTS, the filings are a primary source for details on research and development spending, marketing and general and administrative expenses, net losses, cash and deposits, property and equipment, lease liabilities, warrants, and shareholders’ equity. They also outline risk factors and other considerations referenced in the company’s Form 20-F and related registration statements.
On Stock Titan, users can view Alpha Tau’s SEC submissions as they are made available from EDGAR and use AI-powered summaries to interpret lengthy documents such as financial statements and exhibits. This helps readers quickly understand key points about Alpha Tau’s clinical-stage business model, funding position, and regulatory reporting without manually parsing every line of each filing.
Alpha Tau Medical Ltd. submitted a Form 6-K noting that it issued a press release titled “Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference.” The press release, dated December 18, 2025, is included as an exhibit to the report. The company clarifies that the information in this Form 6-K, including the exhibit, is being furnished rather than filed, which limits its potential liability under U.S. securities laws and controls how it may be incorporated into other regulatory documents.
Alpha Tau Medical Ltd. filed a Form 6-K to furnish a press release titled “Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update,” dated November 20, 2025. The report incorporates this press release by reference into the company’s existing Form F-3 and Form S-8 registration statements.
Alpha Tau Medical Ltd. (DRTS) furnished a Form 6-K noting it issued a press release titled “Alpha Tau Announces Receipt of Radioactive Material License at New Hampshire Manufacturing Facility.”
The submission states the information is being furnished, not deemed filed, and includes the press release as Exhibit 99.1 dated October 21, 2025.
Form 144 notice for Alpha Tau Medical Ltd. (DRTS) reports a proposed sale of 16,000 ordinary shares through Oppenheimer & Co. with an aggregate market value of $72,160. The shares represent a small fraction of the reported 70,380,570 outstanding shares (approximately 0.023%). The securities were acquired on 02/21/2017 under an employee stock options plan and the proposed approximate sale date is 10/01/2025 with payment described as cash upon exercise. The filing indicates no securities sold by the same person in the past three months. Several standard signature and date fields in the remarks section appear in the form but no specific signature, notice date, or plan-adoption date text values are provided in the content supplied.